Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp.'s filings document financial results and operating disclosures for a genomics diagnostics company focused on rare disease testing. Form 8-K reports furnish quarterly and annual results, earnings presentations, preliminary revenue and testing-volume guidance, changes in statement presentation, and modifications to non-GAAP financial measure methodology.
The filing record also covers capital structure and governance matters, including a term loan agreement used to refinance existing debt, Class A common stock and Nasdaq-listed warrant disclosures, board composition changes, and definitive proxy materials. Proxy filings describe director elections, executive compensation, equity awards, stockholder voting matters, and related corporate governance policies.
GeneDx Holdings Corp. reported strong growth for 2025, with revenue rising to $427.5 million, up 41% year over year, and exome and genome test revenue reaching $360.3 million, up 54%. Adjusted gross margin improved to 71% and adjusted net income increased to $41.8 million from $9.4 million in 2024, while GAAP net loss narrowed to $21.0 million.
Fourth-quarter 2025 revenue was $121.0 million, including $104.0 million from exome and genome testing, with test volumes up 34.3% to 27,761. The company ended the year with $172.3 million in cash, cash equivalents, marketable securities and restricted cash and reaffirmed 2026 guidance for revenue of $540–$555 million, 33–35% exome and genome growth, adjusted gross margin of at least 70%, and positive adjusted net income.
GeneDx Holdings Corp. reported strong growth for 2025, with revenue rising to $427.5 million, up 41% year over year, and exome and genome test revenue reaching $360.3 million, up 54%. Adjusted gross margin improved to 71% and adjusted net income increased to $41.8 million from $9.4 million in 2024, while GAAP net loss narrowed to $21.0 million.
Fourth-quarter 2025 revenue was $121.0 million, including $104.0 million from exome and genome testing, with test volumes up 34.3% to 27,761. The company ended the year with $172.3 million in cash, cash equivalents, marketable securities and restricted cash and reaffirmed 2026 guidance for revenue of $540–$555 million, 33–35% exome and genome growth, adjusted gross margin of at least 70%, and positive adjusted net income.
GeneDx Holdings Corp.'s Chief Operating Officer, Dechairo Bryan, reported multiple open‑market sales of Class A Common Stock on February 4, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 15, 2025.
The transactions totaled 5,961 shares sold at weighted average prices ranging from $83.0352 to $91.92 per share, reducing his directly held Class A Common Stock to zero. After these sales, he beneficially owned RSUs covering contingent rights to receive up to 28,123 shares of Class A Common Stock, vesting according to their terms.
GeneDx Holdings Corp. Chief Operating Officer Bryan Dechairo reported RSU vesting and related share sales. On February 1, 2026, 9,374 restricted stock units converted into an equal number of Class A Common shares at $0 per share upon vesting. On February 2, 2026, he sold a total of 3,413 shares in multiple transactions at weighted average prices between $96.7676 and $100.3146 per share to cover tax withholding obligations under a “sell to cover” arrangement, described as non-discretionary. Following these transactions, he directly beneficially owned 5,961 shares of Class A Common Stock and RSUs representing contingent rights to receive up to 28,123 additional shares, vesting over time subject to continued service.
A holder of WGS Class A common stock filed a notice of intent to sell 9,374 shares under Rule 144. The shares have an aggregate market value of 929900 and are part of 28,904,590 shares outstanding. The planned sale date is approximately 02/02/2026 on NASDAQ through Morgan Stanley Smith Barney.
The seller acquired the 9,374 shares of Class A common stock on 01/14/2025 as compensation in the form of restricted stock units from the issuer, with compensation as the nature of payment. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and related share sales. On January 29, 2026, 754 RSUs converted into the same number of Class A Common shares for no cash consideration.
On the same date, Feeley sold 315 shares at $94 and 2 shares at $92.0601. The company states these sales were made solely to cover tax withholding obligations through a “sell to cover” arrangement and were not discretionary trades. After these transactions, Feeley directly held 9,168 Class A Common shares, plus RSUs representing up to 112,750 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity activity tied to restricted stock units. On January 29, 2026 she settled 3,874 RSUs into the same number of Class A common shares for no cash cost, then sold 1,653 shares at a weighted average price of $93.9957 to cover tax withholding obligations through a non‑discretionary “sell to cover” transaction. After these moves she directly owned 16,458 Class A shares, along with RSUs representing contingent rights to receive up to 411,494 additional shares and options to purchase up to 107,610 shares, which vest according to their existing schedules.
A Form 144 notice shows a planned insider sale of 24,155 shares of Class A common stock, with an aggregate market value of $2,369,700. The shares are expected to be sold on or about 01/29/2026 on NASDAQ through Morgan Stanley Smith Barney.
The securities were acquired as compensation in the form of restricted stock units and performance-based restricted stock units on several dates between 2022 and 2025. The document also lists recent sales by Kevin Feeley over the past three months, including blocks such as 3,855 shares on 12/16/2025 for gross proceeds of $554,632.
WGS insider Katherine Stueland has filed a notice of proposed sale of 94,495 shares of Class A common stock through broker Morgan Stanley Smith Barney on NASDAQ. The filing lists an aggregate market value of 9268700 for these shares and shows 28,904,590 shares of this class outstanding.
The shares to be sold were acquired as equity compensation, including restricted stock units and performance-based restricted stock units granted between 2022 and 2025. The notice also reports prior sales over the last three months, including 2,158, 3,639, and 10,857 shares of Class A common stock, with stated gross proceeds for each transaction.
GeneDx Holdings Corp. filed a report stating that it issued a press release on January 12, 2026 outlining its expectations for preliminary, unaudited revenue for the fourth quarter and full year 2025. The update also covers exome and genome test result volumes, GAAP and adjusted gross margin for the same periods, and levels of cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025.
The company additionally provided full year 2026 guidance and released an investor presentation prepared for the 44th Annual J.P. Morgan Healthcare Conference. These materials are furnished as exhibits and are not deemed filed for liability purposes under the securities laws or automatically incorporated into other regulatory documents.
GeneDx Holdings Corp. Chief Financial Officer insider transaction shows routine equity compensation activity. On December 16, 2025, the CFO exercised 7,197 restricted stock units (RSUs), receiving the same number of Class A common shares for no cash consideration. On the same date, multiple small blocks of Class A common stock were sold at weighted average prices between $138.93 and $150.75 per share.
According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the RSU vesting under a “sell to cover” arrangement and were not discretionary trades by the executive. After these transactions, the CFO beneficially owned 8,731 shares of Class A common stock, as well as RSUs representing contingent rights to receive up to 113,504 shares and options to purchase up to 25,906 shares of Class A common stock, all vesting according to their existing terms.